A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...